Eleva
Private Company
Funding information not available
Overview
Eleva Biologics is a German, clinical-stage biotech leveraging a proprietary moss-based platform to develop novel biologics and cell therapies considered inaccessible by conventional systems. The company has built a pipeline initially targeting complement disorders and enzyme replacement therapies, with two candidates already in clinical development. Led by an experienced team, Eleva operates as a private, pre-revenue entity aiming to establish a broad portfolio of unique product candidates, both independently and through partnerships.
Technology Platform
Proprietary moss-based (*Physcomitrella patens*) expression platform for producing complex biologics with intricate glycosylation and post-translational modifications.
Opportunities
Risk Factors
Competitive Landscape
Eleva competes in the complement inhibitor space against companies like Alexion (AstraZeneca), Apellis, and Novartis, and in dry AMD against numerous biotechs. Its primary differentiation is its moss-based production platform, which aims to enable biologics that competitors cannot manufacture, rather than competing on the same targets.